ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / EQ / earnings
NKTX (26) HURA (32) OKUR (34) NERV (31) ⌘ Pro Terminal →

Equillium Inc. (EQ) Next Earnings Date & Expected ±12.5% Move

$1.38 +0.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.38

Equillium Inc. (EQ) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $108.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EQ Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EQ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Equillium Inc. (NASDAQ: EQ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.38 (+0.73% 1D, market cap $108.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EQ ranks #763 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EQ compare to NKTX and HURA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EQ carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NKTX (Nkarta Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $108.9M) and HURA (TuHURA Biosciences Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $109.6M). Among the 5-stock peer group, EQ leads on earnings multiple (N/A) while EQ leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EQ?
▼

Per EQ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001746466), Equillium Inc. generated $66.2M in revenue (+61.0% YoY), -$22.4M in net income, and -$22.8M in free cash flow against $31.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.38 (-0.06%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (3)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.3% Base Target
$4 Bull$1 Base$1 Bear
📬 FREE EQ RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EQ)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY EQ SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
23
Grade E$1.32+4.5% Next Q
Q2 (-2Q)
26
Grade E$1.38-1.4% Next Q
Q3 (-1Q)
28
Grade E$1.36+1.5% Next Q
Current
31
Grade E$1.38-9.4% Hist 90D α
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EQ Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EQ currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.73) and Max Pain ($1.45) forces dealer call-delta covering toward $3.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EQ• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EQ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.17 Expected Swing
$1.21 (-12.5%)Spot $1.38$1.55 (+12.5%)
MODEL EARNINGS SETUP GAUGE

EQ Quantitative Pre-Earnings Setup: 31/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (31/100)Model Risk Weight (69/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$66.2M-$22.4M-$22.8M52%
FY 20242024-12-31$41.1M-$8.1M-$19.1M52%
FY 20232023-12-31$36.1M-$13.3M-$21.8M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EQ)

  • ✓Walkthrough of EQ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
EQ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.33%▼ DESCENDING CHANNEL
2026-11-04O $1.37H $1.38L $1.37C $1.38VOL 337.7K
RES: $2.04SUP: $0.90SMA50: $1.73SMA200: $2.08
$3.71$3.02$2.33$1.64$0.95RES $2.04SUP $0.90$1.382026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EQ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EQ Butterfly Map → + Track EQ →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +61.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EQ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EQ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EQ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EQ)

Health Care Rank #763 of 1015 ⚔️ NKTX vs EQ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EQ vs. NKTX, HURA, OKUR, NERV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Equillium Inc. (EQ) ranks #763 by composite RQD confidence (31/100, grade E) and #639 by equity capitalization ($108.1M). Within this direct 5-issuer industry benchmark cohort, EQ leads on earnings valuation at N/A trailing P/E, while EQ leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OKUR currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with EQ at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EQ ACTIVE
Equillium Inc.
E 31/100 — — -35.0% +0.73% $108.1M Benchmark Subject
NKTX
Nkarta Inc.
E 26/100 — — -35.0% -2.56% $108.9M /nktx-vs-eq →
HURA
TuHURA Biosciences Inc.
E 32/100 — — -35.0% -10.88% $109.6M /hura-vs-eq →
OKUR
OnKure Therapeutics Inc. (Class A)
E 34/100 — — -35.0% -1.14% $104.9M /okur-vs-eq →
NERV
Minerva Neurosciences Inc
E 31/100 — — -35.0% +1.08% $112.0M /nerv-vs-eq →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001746466 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Equillium Inc. (EQ) reported GAAP revenue of $66.2M (+61.0% vs. FY2024 revenue of $41.1M , and +83.4% cumulative change since FY2023) , GAAP net income of -$22.4M, operating cash flow of -$22.7M, and free cash flow of -$22.8M (-19.3% YoY). On the balance sheet, EQ closed FY2025 with $31.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $66.2M -$22.4M -$22.7M -$22.8M $31.9M —
FY2024 (FY) 2024-12-31 $41.1M -$8.1M -$19.0M -$19.1M $25.6M —
FY2023 (FY) 2023-12-31 $36.1M -$13.3M -$21.8M -$21.8M — —

3. EQ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EQ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Equillium Inc. (NASDAQ: EQ) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.38 (+0.73% 1D, market cap $108.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EQ ranks #763 in composite RQD confidence.

How does EQ compare to NKTX and HURA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), EQ carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NKTX (Nkarta Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $108.9M) and HURA (TuHURA Biosciences Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $109.6M). Among the 5-stock peer group, EQ leads on earnings multiple (N/A) while EQ leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EQ?

Per EQ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001746466), Equillium Inc. generated $66.2M in revenue (+61.0% YoY), -$22.4M in net income, and -$22.8M in free cash flow against $31.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EQ trading relative to its 50-day, 200-day, and 52-week technical levels?

EQ last traded at $1.38 (+0.73% on volume of 337,704 shares), positioning the stock -20.23% below its 50-day simple moving average ($1.73) and -33.65% below its 200-day simple moving average ($2.08). Across its 52-week range of $0.76 to $3.54, EQ sits at the 22.3% percentile with a 14-day RSI of 44.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.21 to $1.55).

Direct Sub-Reports: EQ RQD Cockpit EQ 12M Forecast EQ Earnings & Move EQ Dividends & DRIP EQ Insiders & 13F EQ Whale Options EQ Profit Sankey EQ News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

EQ — Equillium Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Equillium Inc. (EQ) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.38 (+0.73% 1D, market capitalization $108.1M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -20.48%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Equillium Inc. (EQ) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.1B. FY 2025 revenue is —, down from $41.1M in FY 2024 and $36.1M in FY 2023. — describes what products the company sells, to whom, or how it earns revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Equillium Inc. (EQ) reported $66.2M in annual revenue (up from $41.1M in FY2024, +61.0% YoY) and -$22.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($36.1M revenue, -$13.3M net income) through FY2025, EQ scaled operating cash flow to -$22.7M and free cash flow to -$22.8M, backed by $31.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -20.48% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.76 – $3.54 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), EQ carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can EQ sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $66.2M and free cash flow of -$22.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is EQ's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

EQ Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Equillium Inc. (EQ) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EQ Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EQ Bull vs. Bear Conversation Board — What's Your Call at $1.38?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EQ 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EQ:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.66 (+21.2%)
📌 Pinned Debate

Clinical progress on EQ504, including first patient dosed in a phase 1 trial, and a Buy rating with a $6 target from Leerink Partners.

Clinical progress on EQ504, including first patient dosed in a phase 1 trial, and a Buy rating with a $6 target from Leerink Partners.. When you look under the hood at EQ, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $3.54. My 12M target is $1.66.

EarningsSniper 🐂 BULL

@BearTrap_Alert Shorting a 3/20 institutional whale-flow stock at $1.37 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.03 (-24.8%)
Spot @ $1.37

Negative ROIC of -35%, negative FCF yield of -20.48%, and a Piotroski F-Score of 1 out of 9 indicate weak cash generation and fundament

Careful chasing EQ at $1.37. Negative ROIC of -35%, negative FCF yield of -20.48%, and a Piotroski F-Score of 1 out of 9 indicate weak cash generation and fundamentals.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.03 on multiple compression.

LIVE TAPE